The closing price of Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) was $1.07 for the day, down -6.14% from the previous closing price of $1.14. In other words, the price has decreased by -$0.0700 from its previous closing price. On the day, 697649 shares were traded. RIGL stock price reached its highest trading level at $1.1400 during the session, while it also had its lowest trading level at $1.0600.
Our analysis of RIGL’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.00 and its Current Ratio is at 2.30.
Upgrades & Downgrades
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 06 when RODRIGUEZ RAUL R sold 20,340 shares for $1.75 per share. The transaction valued at 35,595 led to the insider holds 1,680,713 shares of the business.
Dummer Wolfgang sold 5,389 shares of RIGL for $8,946 on Feb 02. The EVP & CMO now owns 72,459 shares after completing the transaction at $1.66 per share. On Feb 02, another insider, Schorno Dean L, who serves as the EVP & Chief Financial Officer of the company, sold 5,389 shares for $1.66 each. As a result, the insider received 8,946 and left with 196,519 shares of the company.
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RIGL now has a Market Capitalization of 186.57M and an Enterprise Value of 182.88M. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.47. Its current Enterprise Value per Revenue stands at 1.41 whereas that against EBITDA is -4.59.
Stock Price History:
Over the past 52 weeks, RIGL has reached a high of $2.04, while it has fallen to a 52-week low of $0.67. The 50-Day Moving Average of the stock is 1.2084, while the 200-Day Moving Average is calculated to be 1.3611.
RIGL traded an average of 1.23M shares per day over the past three months and 955.47k shares per day over the past ten days. A total of 173.75M shares are outstanding, with a floating share count of 171.87M. Insiders hold about 1.44% of the company’s shares, while institutions hold 77.60% stake in the company. Shares short for RIGL as of Aug 14, 2023 were 3.72M with a Short Ratio of 3.82M, compared to 3.85M on Jul 13, 2023. Therefore, it implies a Short% of Shares Outstanding of 2.13% and a Short% of Float of 2.16%.
The firm’s stock currently is rated by 6 analysts. On average, analysts expect EPS of -$0.07 for the current quarter, with a high estimate of -$0.06 and a low estimate of -$0.09, while EPS last year was -$0.11. The consensus estimate for the next quarter is -$0.07, with high estimates of -$0.06 and low estimates of -$0.09.
Analysts are recommending an EPS of between -$0.24 and -$0.29 for the fiscal current year, implying an average EPS of -$0.26. EPS for the following year is -$0.14, with 6 analysts recommending between -$0.1 and -$0.2.
It is expected that $90B in revenue will be generated in the current quarter, according to 5 analysts. It ranges from a high estimate of $28.82M to a low estimate of $24.7M. As of the current estimate, Rigel Pharmaceuticals Inc.’s year-ago sales were $22.61M, an estimated increase of 20.30% from the year-ago figure. For the next quarter, 5 analysts are estimating revenue of $28.95M, a decrease of -43.50% less than the figure of $20.30% in the same quarter last year. There is a high estimate of $30.97M for the next quarter, whereas the lowest estimate is $25.7M.
A total of 6 analysts have provided revenue estimates for RIGL’s current fiscal year. The highest revenue estimate was $124.64M, while the lowest revenue estimate was $103.3M, resulting in an average revenue estimate of $111.2M. In the same quarter a year ago, actual revenue was $120.24M, down -7.50% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $135.69M in the next fiscal year. The high estimate is $143.9M and the low estimate is $111.01M. The average revenue growth estimate for next year is up 22.00% from the average revenue estimate for this year.